Clinical Trial Update: Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects [Phase 3]

View source ↗

Summary

Phase 3 open-label extension trial update evaluating Rotigotine for idiopathic restless legs syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Restless Legs Syndrome

Drugs mentioned

• Neupro (rotigotine)

Snippet

Sponsor: UCB Pharma | Conditions: Idiopathic Restless Legs Syndrome | Phase 3 | Status: COMPLETED